GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (NAS:AONCW) » Definitions » ROE %

American Oncology Network (American Oncology Network) ROE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. American Oncology Network's annualized net income for the quarter that ended in Mar. 2024 was $-31.36 Mil. American Oncology Network's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-99.60 Mil. Therefore, American Oncology Network's annualized ROE % for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for American Oncology Network's ROE % or its related term are showing as below:

During the past 4 years, American Oncology Network's highest ROE % was 4.26%. The lowest was -0.18%. And the median was 2.04%.

AONCW's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 4.445
* Ranked among companies with meaningful ROE % only.

American Oncology Network ROE % Historical Data

The historical data trend for American Oncology Network's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network ROE % Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
- -0.18 4.26 -

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial 16.70 - - - -

Competitive Comparison of American Oncology Network's ROE %

For the Medical Care Facilities subindustry, American Oncology Network's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Oncology Network's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, American Oncology Network's ROE % distribution charts can be found below:

* The bar in red indicates where American Oncology Network's ROE % falls into.



American Oncology Network ROE % Calculation

American Oncology Network's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-5.542/( (62.016+-96.741)/ 2 )
=-5.542/-17.3625
=N/A %

American Oncology Network's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-31.364/( (-96.741+-102.46)/ 2 )
=-31.364/-99.6005
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


American Oncology Network  (NAS:AONCW) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-31.364/-99.6005
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-31.364 / 1457.356)*(1457.356 / 398.187)*(398.187 / -99.6005)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2.15 %*3.66*N/A
=ROA %*Equity Multiplier
=-7.87 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-31.364/-99.6005
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-31.364 / -88.464) * (-88.464 / -75.544) * (-75.544 / 1457.356) * (1457.356 / 398.187) * (398.187 / -99.6005)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.3545 * 1.171 * -5.18 % * 3.66 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


American Oncology Network ROE % Related Terms

Thank you for viewing the detailed overview of American Oncology Network's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network (American Oncology Network) Business Description

Traded in Other Exchanges
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.